Menstrual disorders frequently occur during a woman’s reproductive years, leading to notable physical and psychological distress, according to details published by The Hindu. Normal menstruation typically begins at menarche around age 12 and continues until menopause near age 50. Controlled by the hypothalamo-pituitary-ovarian axis, a standard cycle involves cyclical changes in the ovary and the inner uterine lining, known as the endometrium. Normal menstrual flow usually lasts between two and seven days and recurs every 21 to 35 days.
Understanding Abnormal Uterine Bleeding and Clinical Presentations
In contrast, abnormal uterine bleeding involves bleeding that extends beyond seven days, heavy flow accompanied by clots, bleeding severe enough to stain clothing or cause anemia, cycles shorter than 21 days or longer than 35 days, intermenstrual bleeding, or post-menopausal bleeding. As reported by American Family Physician, abnormal uterine bleeding is a common and complicated clinical presentation in family practice settings. One national study cited by the publication found that menstrual disorders accounted for 19.1 percent of 20.1 million visits to physician offices for gynecologic conditions across a two-year period, with approximately 25 percent of gynecologic surgeries involving abnormal uterine bleeding.
Evaluation and Underlying Causes Across Age Groups
The causes of abnormal uterine bleeding vary significantly depending on a patient’s age and life stage. For teenagers, potential factors include anovulation, pelvic infection, hormonal pill use, coagulation disorders, and hormone-producing tumors. During reproductive years, causes involve pregnancy, polyps, adenomyosis, fibroids, anovulation, endometrial hyperplasia, and endometrial cancers. In perimenopausal and postmenopausal populations, common causes shift to anovulation, endometrial hyperplasia, endometrial cancer, and endometrial atrophy.
Medical evaluations for abnormal bleeding are guided by patient age, family history of cancers, functional disability, and the desire for fertility. Initial investigations often include checking hemoglobin levels, renal and liver function, coagulation disorders, ultrasound scans, cervical cytology, and endometrial biopsies. For postmenopausal women, malignancy and hyperplasia must be ruled out, as the risk of malignancy associated with post-menopausal bleeding ranges from 10 to 20 percent.
Diagnostic Approaches and International Guidelines
Pre-operative work-ups for potential endometrial abnormalities utilize multiple diagnostic modalities, including hysteroscopy to evaluate and help remove lesions such as polyps. According to findings reviewed in PMC, endometrial carcinoma stands as the most common gynecological cancer, accounting for 417,367 new cases worldwide in 2020 and nearly 100,000 deaths. Nearly 90 percent of women with endometrial carcinomas experience abnormal vaginal bleeding, predominantly during the postmenopausal period.
Leading international societies provide distinct directives for histological diagnosis and pre-operative sampling:
- ESMO Guidelines: Do not take a position on the single best type of endometrial sampling, stating that both biopsy and dilatation and curettage (D&C) are acceptable initial approaches to histological diagnosis.
- ESGO–ESTRO–ESP Panel: Does not express a specific position regarding the preferred type of endometrial sampling.
- Post-menopausal Recommendations: Post-menopausal women experiencing abnormal uterine bleeding may be offered dilatation and curettage, or transvaginal ultrasonography and saline-infusion sonohysterography with directed endometrial biopsy if they are poor candidates for general anesthesia or decline D&C.
Management Strategies: Medical and Surgical Options
Management strategies for abnormal uterine bleeding encompass both medical and surgical interventions tailored to the underlying etiology. Medical treatments designed to control bleeding and pain include tranexamic acid, mefenamic acid, oral and injectable progestogens, combined oral contraceptive pills, levonorgestrel intrauterine devices or contraceptive systems, mifepristone, ormeloxifene, and gonadotrophin analogues.
Surgical management ranges from uterus-sparing procedures to endoscopic surgeries performed laparoscopically, robotically, or hysteroscopically. While surgery in younger women is most often organ-preserving, an endometrial biopsy is considered mandatory prior to hysterectomy in perimenopausal and postmenopausal patient groups to rule out underlying malignancy or hyperplasia.
